Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery
← catalyst calendarSponsored by Glaukos Corporation (industry) · GKOS — their whole pipeline →.
Phase
—
Status
Unknown status
Study type
Observational
Enrollment
200estimated
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-10-04 | actual | When the study began enrolling |
| Primary completion | Feb 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2017-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Corneal Ectasia
Intervention
- Combination product: Corneal Collagen Cross-linking
Primary outcomes
what the primary-completion date above is the date OFKmax
measured 36 months
BCVA
measured 36 month
Publications
- PMID 28655538 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GKOS's whole pipeline · Catalyst calendar · Every registered study · What changed